Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
They bring the accuracy and sensitivity of immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. They are also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Adaptive Biotechnologies or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.